Thymosin alpha-1: what this immune peptide is
The short version: thymosin alpha-1 is a small protein the body’s immune-training organ produces. A synthetic version is approved in many countries — but not in the U.S.
TL;DR
- Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland.
- It supports T-cell maturation and immune signaling.
- Approved internationally as Zadaxin; in the U.S. it is accessed as a compounded preparation under physician prescription.
What it is
Thymosin alpha-1 (in plain English: a small protein the thymus gland produces to help train the immune system) is a peptide first isolated from calf thymus extract in the 1970s. The thymus is the small immune-training organ behind the breastbone where T-cells learn to tell self from non-self. Thymosin alpha-1 is one of several signaling peptides the thymus releases. The synthetic version goes by two names: thymalfasin (the generic) and Zadaxin (the brand).
How it works
Think of T-cells as airport security screeners. They have to learn what is “normal traveler” and what is “threat.” The thymus is the training academy. Thymosin alpha-1 is one of the instructors — it nudges immature T-cells toward maturity and helps activate the immune system’s first responders (Goldstein & Garaci, Vaccine, 2009). The thymus shrinks with age, and thymic hormone levels drop alongside it. That is why thymosin alpha-1 has been a topic of interest in older-adult immune research.
Who asks about it
People come to thymosin alpha-1 after reading about immune support in the context of aging, repeat infections, or post-illness recovery. About 6 in 10 adults over 70 have measurable signs of immune aging in published cohorts. The peptide is one of several tools clinicians explore in this space.
What the research says
Thymosin alpha-1 has been studied in chronic hepatitis B, chronic hepatitis C, sepsis, and as an adjuvant in some cancer settings (Costantini et al., Expert Opin Biol Ther, 2015). Outside the U.S., thymalfasin is approved in over 35 countries, primarily for hepatitis B. In the U.S., it is not FDA-approved. Its broader immune-modulation use in functional and longevity medicine is largely off-label.
What to know before considering it
Thymosin alpha-1 requires a licensed clinician evaluation. People with autoimmune disease, recent organ transplant, or active immunosuppressant therapy are typically not candidates. The compounded version is not FDA-approved. Side effects in trials are generally mild but include injection-site reactions and occasional flushing.
The Halftime POV
Thymosin alpha-1 is one of the more clinically grounded peptides in the longevity conversation — it has international approval and decades of trial data. Whether it belongs in any one person’s protocol is a clinical decision, not a default.
Related reading:
- Thymosin alpha-1 research: where it has been studied
- How thymosin alpha-1 signals the immune system: the mechanism
- Thymosin alpha-1 side effects and contraindications
FAQ
Q: What is thymosin alpha-1? A: Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland. It plays a role in T-cell maturation and immune signaling. A synthetic version is sold internationally as Zadaxin and used in some cancer and infection settings.
Q: Where does thymosin alpha-1 come from? A: It is naturally produced in the thymus, the small immune-organ behind the breastbone that trains T-cells in early life. The thymus shrinks with age. The peptide can also be made synthetically for medical use.
Q: Is thymosin alpha-1 FDA-approved in the U.S.? A: Thymalfasin (Zadaxin) is approved in dozens of countries but is not FDA-approved in the United States. Compounded thymosin alpha-1 is prescribed off-label and prepared by state-licensed 503A pharmacies. The compounded version is not FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
